 |
|
Migraine prevention by targeting glutamate receptors?
April 29, 2009Data to be presented at AAN suggests glutamate receptor 'mGluR5' is clinically relevant
When migraine strikes, because of severe pain, often accompanied by nausea and sensitivity to light and sound, sufferers are effectively disabled for up to 72 hours. Since they are forced to stop what they are doing until the pain and other symptoms subside, migraine causes a significant loss in productivity at work and the personal lives of those affected. Migraineurs - especially the 25% of migraineurs who experience more than three migraine attacks per month - are looking to drug developers to provide new drugs to prevent migraine attacks before they start. In the U.S. alone, approximately 30 million people suffer from migraines and the cost to employers has been estimated at $13 billion annually in lost productivity. Currently, several types of drugs, like generic beta blockers, calcium channel blockers, tricyclic antidepressants and anti-epileptic drugs, some of which are used off-label, are given to prevent migraines. However, many patients have only a partial response to these products, many of which have troubling side effects. Nevertheless, many migraine patients use existing drugs, illustrating how badly new drugs are needed.
Given the role of glutamate in the pathophysiology of migraine, the future of migraine prophylaxis, may lie in modulating one of the receptors in the glutamate system, mGluR5.
At the forthcoming annual meeting of the American Academy of Neurology in Seattle (April 25 - May 2), Addex Pharmaceuticals (SIX: ADXN) will present Phase IIa data on ADX10059, a negative mGluR5 allosteric modulator, which shows efficacy in treating acute migraine attacks and provides evidence that inhibition of this glutamate receptor subtype could play a role in stopping migraine attacks before they start.
Preclinical experiments and small scale studies in migraineurs with drugs like ketamine, which acts on glutamate signaling through NMDA receptors (functionally related to mGluR5) and the NMDA antagonist memantine, suggest that mGluR5 could play a role in the "migraine circuit," a positive feedback loop that generates the symptoms of a migraine attack. The initial step to test this hypothesis was Addex' proof of concept study in acute treatment of migraine attacks.
In the Phase IIa clinical trial of 129 migraine patients, significantly more patients taking ADX10059 than those taking placebo (16.7% vs 4.7%, respectively p = 0.039) were pain-free two hours after dosing. ADX10059 administration yielded better pain improvement than placebo at all time points up to two hours after treatment of a migraine attack. In addition, there were trends to superiority for ADX10059 over placebo for migraine pain improvement (mild or no pain) at all time points up to two hours post-dosing.
"Medication is available to prevent migraine but these treatments are often secondary uses of the drug and come with potentially limiting side-effects," noted Dr. Peter Goadsby of the UCSF Headache Center. "New therapies specifically developed for migraine prevention are urgently needed especially for the substantial proportion of migraine sufferers who have frequent attacks and have significant disability in their daily lives. Targeting mGluR5 signaling with ADX10059 is an interesting approach that is showing significant promise in early clinical evaluation."
"The clinical trial data for ADX10059, presented here at AAN, proved the concept that by terminating acute attacks in some patients, mGluR5 inhibition plays a role in migraine pathophysiology. Now we are looking forward to the data from our ongoing Phase IIb migraine prevention study in the first half of 2010," said Charlotte Keywood, chief medical officer.
In December 2008, Addex initiated a Phase IIb trial to study ADX10059 as a prophylactic agent in migraine. The 12-week trial will compare ADX10059 (25mg, 50mg or 100mg) versus placebo in migraine patients who suffer three or more attacks per month. Data from the migraine prevention trial are expected in the first half of 2010.
Halsin Partners
At the forthcoming annual meeting of the American Academy of Neurology in Seattle (April 25 - May 2), Addex Pharmaceuticals (SIX: ADXN) will present Phase IIa data on ADX10059, a negative mGluR5 allosteric modulator, which shows efficacy in treating acute migraine attacks and provides evidence that inhibition of this glutamate receptor subtype could play a role in stopping migraine attacks before they start.
Preclinical experiments and small scale studies in migraineurs with drugs like ketamine, which acts on glutamate signaling through NMDA receptors (functionally related to mGluR5) and the NMDA antagonist memantine, suggest that mGluR5 could play a role in the "migraine circuit," a positive feedback loop that generates the symptoms of a migraine attack. The initial step to test this hypothesis was Addex' proof of concept study in acute treatment of migraine attacks.
In the Phase IIa clinical trial of 129 migraine patients, significantly more patients taking ADX10059 than those taking placebo (16.7% vs 4.7%, respectively p = 0.039) were pain-free two hours after dosing. ADX10059 administration yielded better pain improvement than placebo at all time points up to two hours after treatment of a migraine attack. In addition, there were trends to superiority for ADX10059 over placebo for migraine pain improvement (mild or no pain) at all time points up to two hours post-dosing.
"Medication is available to prevent migraine but these treatments are often secondary uses of the drug and come with potentially limiting side-effects," noted Dr. Peter Goadsby of the UCSF Headache Center. "New therapies specifically developed for migraine prevention are urgently needed especially for the substantial proportion of migraine sufferers who have frequent attacks and have significant disability in their daily lives. Targeting mGluR5 signaling with ADX10059 is an interesting approach that is showing significant promise in early clinical evaluation."
"The clinical trial data for ADX10059, presented here at AAN, proved the concept that by terminating acute attacks in some patients, mGluR5 inhibition plays a role in migraine pathophysiology. Now we are looking forward to the data from our ongoing Phase IIb migraine prevention study in the first half of 2010," said Charlotte Keywood, chief medical officer.
In December 2008, Addex initiated a Phase IIb trial to study ADX10059 as a prophylactic agent in migraine. The 12-week trial will compare ADX10059 (25mg, 50mg or 100mg) versus placebo in migraine patients who suffer three or more attacks per month. Data from the migraine prevention trial are expected in the first half of 2010.
Halsin Partners
Migraine Current Events and Migraine News RSSResearch: Migraine and cardiovascular disease: Systematic review and meta-analysis
Migraine with aura (temporary visual or sensory disturbances before or during a migraine headache) is associated with a twofold increased risk of stroke, finds a study published on bmj.com today.
Increased stroke risk from birth control pills
She was only 30 years old, but she was experiencing the classic symptoms of a stroke. Her speech suddenly became slurred, and her left hand became clumsy while eating.
Surgery potentially best option for severe migraine headaches
The disability from migraine headaches is an enormous health burden affecting over 30 million Americans.
Migraine sufferers more prone to hangover headache
Migraine sufferers, beware. You may be more prone to an alcohol-induced headache after a night of drinking, according to researchers from the Jefferson Headache Center. The research will be presented at Neuroscience 2009, the Annual Meeting of the Society for Neuroscience, in Chicago.
Jefferson Headache Center study shows novel, orally inhaled migraine therapy effective
A new study conducted at the Jefferson Headache Center at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania shows an investigational, orally-inhaled therapy is effective in treating migraines.
Neck surgery for cervical spine disorders found to alleviate associated headaches
A new study published in the August 2009 issue of the Journal of Bone and Joint Surgery (JBJS) finds that two years after anterior cervical neck operations, patients who have arthroplasty (disc replacement) or arthodesis (spine fusion) can be expected to have significant improvement in their headache symptoms.
Got migraines?
Migraine headaches are a drain - not only on the estimated 30 million Americans who suffer from them, but on the economy, too.
Anti-epilepsy drug risk on cognitive function for unborn children
Interim results of a study being conducted by scientists at the University of Liverpool suggest that children aged three years and younger, who are born to women taking the anti-epileptic drug sodium valproate whilst pregnant, are likely to have an IQ of six to nine points lower than average.
Link between migraines and reduced breast cancer risk confirmed in follow-up study
The relationship between migraine headaches in women and a significant reduction in breast cancer risk has been confirmed in a follow-on study to landmark research published last year and conducted by scientists at Fred Hutchinson Cancer Research Center.
Learning from locusts
A similarity in brain disturbance between insects and people suffering from migraines, stroke and epilepsy points the way toward new drug therapies to address these conditions.
More Migraine Current Events and Migraine News Articles
 |
Migraine by Oliver Sacks (Author) "Balanced, authoritative . . . brilliant." --The London Times "Written by one of the great clinical writers of the twentieth century, Migraine . . . should be read as much for its brilliant insights into the nature of our mental functioning as for its discussion of the migraine." --The New York Times Book Review The many manifestations of migraine can vary dramatically from one patient to another, even within the same patient at different times. Among the most compelling and perplexing of these symptoms are the strange visual hallucinations and distortions of space, time, and body image which migraineurs sometimes experience. Portrayals of these uncanny states have found their way into many works of art, from the heavenly visions of Hildegard von Bingen to... |
 |
Quantum - Migrelief, 60 tablets by Quantum Doctors and patients are finding MigreLief's triple therapy approach, used over a period of time, is an important tool for the prevention and reduction of severity. The triple stands for the three key ingredients; magnesium, feverfew and riboflavin. Dr. Alexander Mauskop, one of the world's leading migraine researchers and Director of the New York Headache Clinic has been working with his own triple therapy since 1992. His research has been crucial in establishing MigreLief's credentials as a superior product. Only MigreLief contains Puracol, a specially sourced whole herb feverfew with all of its naturally occurring elements intact and a high - parthenolide content. MigreLief uses specific forms of each ingredient, which is one reason it is so highly regarded. The quality of the... |
 |
Heal Your Headache: The 1-2-3 Program for Taking Charge of Your Pain by David Buchholz (Author), Stephen G. Reich M.D. (Foreword) Based on the breakthrough understanding that virtually all headaches are forms of migraine--because migraine is not a specific type of headache, but the built-in mechanism that causes headaches of all kinds, along with neck stiffness, sinus congestion, dizziness, and other problems--Dr. Buchholz's HEAL YOUR HEADACHE puts headache sufferers back in control of their lives with a simple, transforming program: Step 1: Avoid the "Quick Fix." Too often painkillers only make matters worse because of the crippling complication known as rebound. Step 2: Reduce Your Triggers. The crux of the program: a migraine diet that eliminates the foods that push headache sufferers over the top. Step 3: Raise Your Threshold. When diet and other lifestyle changes aren't enough, preventive... |
 |
MigreLief Migraine Dietary Supplement, 60 Tablets (Pack of 2) by MigreLief Doctors around the country are recommending MigreLief a patented, non-prescription dietary supplement that treats the underlying nutritional deficiencies that clinical studies show may play a role in reducing migraine frequency and severity |
 |
Living Well with Migraine Disease and Headaches: What Your Doctor Doesn't Tell You...That You Need to Know by Teri Robert (Author) For millions of Americans, Migraine disease, tension headaches, and other headaches are a debilitating part of every day. Teri Robert has been there—in fact, she experienced her first Migraine at age six. Now, in this groundbreaking holistic guide to the diagnosis and treatment of headaches and Migraine disease, she brings a patient-empowering message to all headache sufferers: you don't have to live with daily pain. She provides you with all the information you need to know about getting the help you need, including: Understanding side effects Treatments for long-term relief Risks and symptoms Identification of the various types of headaches Traditional and alternative therapies Information on finding health care practitioners and support Numerous case studies and expert advice... |
 |
Well Patch Cooling Headache Pads, Migraine, 4 - 2 in x 5 1/8 in pads (Pack of 6) by WellPatch Lasts up to 8 hours. Cooling Therapy for migraine and headache discomfort. Safe to use with medications. Great for both children and adults. Soft, comfortable, & easy to apply. Soothe the discomfort associated with migraine and headache wit Well Patch Migraine Cooling Headache Pads, a cooling therapy to supplement your regular treatment routine. Convenient and portable, Well Patch Migraine Cooling Headache Pads can be used at home, at work, traveling, or anywhere. Can be used for adults and children. Each soft, flexible pad stays comfortably in place. Cools immediately and lasts up to 8 hours. Doctors recommend cooling therapy. Well Patch Migraine Cooling Headache Pads are drug-free and safe to use with medications. Use Well Patch Migraine Cooling Headache Pads wherever you need it most.... |
 |
The Migraine Brain: Your Breakthrough Guide to Fewer Headaches, Better Health by Carolyn Bernstein (Author), Elaine McArdle (Author) You know that your migraine isn't just a headache. But you may not know that migraine actually is a neurological disease. Affecting one in five women, one in twenty men, and one in twenty children, it's a debilitating, complex, and chronic condition that manifests in a combination of symptoms that can include excruciating head pain as well as other distinctive physical and emotional effects. Yet it's also a disease that you can get control of, improve, and manage, as Dr. Carolyn Bernstein has discovered in her seventeen years as a Harvard Medical School faculty member and practicing neurologist. Praised for her excellence and compassion, the founder of the Women's Headache Center near Boston, and a migraine sufferer herself, Dr. Bernstein has helped hundreds of her patients get better.... |
 |
A Brain Wider Than the Sky: A Migraine Diary by Andrew Levy (Author) With more than one in ten Americans -- and more than one in five families -- affected, the phenomenon of migraine is widely prevalent and often ignored or misdiagnosed. By his mid-forties, Andrew Levy's migraines were occasional reminders of a persistent illness that he'd wrestled with half his life, though he had not fully contemplated their physical and psychological influence on the individual, family, and society at large. Then in 2006 Levy was struck almost daily by a series of debilitating migraines that kept him essentially bedridden for months, imprisoned by pain and nausea that retreated only briefly in gentler afternoon light. When possible, Levy kept careful track of what triggered an onset -- the "thin, taut" pain from drinking a bourbon, the stabbing pulse brought on by a... |
 |
Wellpatch Migraine, Cooling Headache pads - 4 each by MENTHOLATUM INC INDICATIONS:New and Improved! Lasts up to 8 hours Safe to use with medications Safe for children Cooling comfort for migraine, headache, and fever 4 Pads 2" x 5-1/8" WellPatch Migraine Cooling Headache Pads should be part of your Migraine Management Progr |
 |
Migraines Be Gone: 7 Simple Steps to Eliminating Your Migraines Forever by Kelsie (Author), Kenefick (Author) |
| © 2009 BrightSurf.com |